Evidence map›Paper›PMID 33006786›Full record

ArticleCancer science2020

Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.

Taeko Hayakawa, Tomonori Yaguchi, Yutaka Kawakami

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Taeko HayakawaDivision of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8539-8051
Tomonori YaguchiDivision of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
Yutaka KawakamiDivision of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
Keio University · JP

Funding

a grant from Tokyo Biochemical Research FoundationA Keio Gijuku Academic Development FundsJapan Agency for Medical Research and Development (AMED)The Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan 23240128The Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan 26221005The Ministry of Health, Labor and Welfare (MHLW) of Japan H22The Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) 14069014 and the Project for Cancer Research And Therapeutic Evolution (P-CREATE)
6 · The paper itself

Abstract

PD-1/PD-L1 immune checkpoint inhibitors are promising cancer immunotherapies however responses are still limited and the development of more effective combination immunotherapy is needed. We previously reported that STAT3 activation in cancer cells and immune cells was involved in immune-resistant mechanisms. In this study, we evaluated the effect of highly absorptive forms of curcumin extracts and synthetic curcumin on anti-tumor T cell responses. The curcumin po administration resulted in the significant augmentation of in vivo induction of tumor antigen-specific T cells through restoration of dendritic cells (DCs) by inhibiting directly STAT3 in DCs and indirectly via reduced IL-6 production from STAT3 activated cancer cells in 2 syngeneic MC38 and CT26 murine tumor models. Curcumin also showed direct DC enhancing activity and enhanced T cell induction for the immunized antigens in non-tumor-bearing mice and human hosts. Curcumin restored DC functions in xenogeneic nude mouse model implanted with high IL-6-producing human clear cell ovarian cancer cells. The combination of curcumin and PD-1/PD-L1 Abs demonstrated a synergistic anti-tumor activity in MC38 murine tumor models. These results indicated that curcumin augments the induction of tumor antigen-specific T cells by restoring the T cell stimulatory activity of DCs targeting activated STAT3 in both cancer cells and immune cells. Combination immunotherapy with curcumin and PD-1/PD-L1 Ab is an attractive strategy in the development of effective immunotherapy against various cancers.

Indexed as

AnimalsAntineoplastic AgentsCurcuminDendritic CellsDrug Therapy, CombinationFemaleHumansImmune Checkpoint InhibitorsImmunotherapyInterferon-gammaInterleukin-6MiceMice, Inbred BALB CMice, Inbred C57BLMice, NudeNeoplasmsAntineoplastic AgentsCurcuminImmune Checkpoint InhibitorsInterferon-gammaInterleukin-6NF-kappa BPlant ExtractsSTAT3 protein, humanSTAT3 Transcription Factorcancer immunotherapycurcumindendritic cellsPD-1/PD-L1 blockadeSTAT3

Identifiers

PMID33006786
PMCPMC7734012
OpenAlexW3090016951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.